Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 51.09 -3.18% -1.68
ONCE closed down 3.18 percent on Tuesday, February 19, 2019, on 1.91 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ONCE trend table...

Date Alert Name Type % Chg
Feb 19 Slingshot Bullish Bullish Swing Setup 0.00%
Feb 19 Upper Bollinger Band Walk Strength 0.00%
Feb 19 Earnings Movers Other 0.00%
Feb 19 Multiple of Ten Bullish Other 0.00%
Feb 19 Weak + Overbought Other 0.00%
Feb 19 Outside Day Range Expansion 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 19 Upper Bollinger Band Touch Strength 0.00%
Feb 15 Above Upper BB Strength -3.18%
Feb 15 Overbought Stochastic Strength -3.18%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Neurodegenerative Diseases Retinitis Pigmentosa Blindness Gene Delivery Treatment Of Hemophilia Gene Therapy Products Genetic Diseases Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 96.59
52 Week Low 34.53
Average Volume 523,371
200-Day Moving Average 58.8308
50-Day Moving Average 43.146
20-Day Moving Average 46.783
10-Day Moving Average 49.051
Average True Range 2.3103
ADX 32.36
+DI 29.6917
-DI 9.612
Chandelier Exit (Long, 3 ATRs ) 46.3391
Chandelier Exit (Short, 3 ATRs ) 47.5709
Upper Bollinger Band 53.1015
Lower Bollinger Band 40.4645
Percent B (%b) 0.84
BandWidth 27.011949
MACD Line 2.2431
MACD Signal Line 1.8355
MACD Histogram 0.4076
Fundamentals Value
Market Cap 1.6 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -8.00
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.73
Resistance 3 (R3) 56.83 55.05 55.79
Resistance 2 (R2) 55.05 53.61 55.00 55.48
Resistance 1 (R1) 53.07 52.73 52.18 52.97 55.16
Pivot Point 51.29 51.29 50.85 51.24 51.29
Support 1 (S1) 49.31 49.85 48.42 49.21 47.02
Support 2 (S2) 47.53 48.97 47.48 46.70
Support 3 (S3) 45.55 47.53 46.39
Support 4 (S4) 45.45